Drug intelligence / Profile preview

GSK-376501

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK-376501 is an investigational small molecule drug developed by GSK (GlaxoSmithKline) as an oral partial agonist of the peroxisome proliferator–activated receptor gamma (PPARγ). It was studied in phase I clinical trials for the treatment and diagnosis of type 2 diabetes mellitus and also evaluated in healthy overweight and obese subjects. The compound was designed to modulate PPARγ activity, a nuclear receptor involved in glucose metabolism and adipogenesis, but development was discontinued after early-phase studies[1][2][3][4][5].

Other names: 1010412-80-2UNII 7511RY999UUNII7511RY999UUNII-7511RY999U

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on GSK-376501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK-376501.

Explore the full profile